Barrons.com
Biotech Is Due for a Comeback. 5 Stocks That Could Lead a Revival.
The market is littered with biotech stocks whose prices have fallen by more than half since the start of the year. The list of big losers is long and, for biotech investors, more than a bit painful. The fallen stocks include established mid-cap biotech names like bluebird bio (ticker: BLUE), now down 57.7% on the year; Acadia Pharmaceuticals (ACAD), down 66.9%; and AbCellera Biologics (ABCL), down 57.9%.